Monographie - Acetazolamide - Stabilis 4.0

Ultimo aggiornamento :
08/05/2024

Diuretico

Acetazolamide

Iniezione

Soluzione orale

Stabilità in soluzione

Stabilità in miscela

Fattori che influenzano la stabilità

Compatibilità

Metodo di iniezione

Bibliografia

Pdf

Struttura chimica

Nome commerciale

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acetazolamide	Canada, Malaysia, Stati Uniti d’America
Diamox	Arabia Saudita, Australia, Austria, Belgio, Finlandia, Francia, Gran Bretagna, Iran, Irlanda, Lussemburgo, Paesi Bassi, Slovenia, Svezia, Svizzera
Glaumox	Nuova Zelanda

Bibliografia

Iniezione

Bibliografia : Acetazolamide

	Tipo	Pubblicazione
198	Rivista	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
316	Rivista	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
460	Rivista	Parasrampuria J, Das Gupta V, Stewart KR. Stability of acetazolamide sodium in 5% dextrose and 0.9% sodium chloride injection. Am J Hosp Pharm 1987 ; 44: 358-360.
1201	Rivista	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
2090	Rivista	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
4389	Rivista	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4603	Rivista	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.

Mentions Légales